Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash ...

FOSHAN, GUANGDONG, CHINA, January 14, 2026 /EINPresswire.com/ -- Foshan AoChuanShun New Material Industrial Co., Ltd.

Key market opportunities in CD137-targeted therapies include the upcoming commercial launch by 2030, robust clinical trial activity with over 90 therapies, and promising combination therapies.

Corvus Pharmaceuticals, Inc. jumps 165% on Phase 1 soquelitinib atopic dermatitis data; learn key efficacy, funding, and ...

A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Track bar adjustments sound like garage jargon until you see how much they change the car’s balance. On a NASCAR stock c ...

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.

IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

Nanoscope Therapeutics has received Pioneering Regenerative Medical Product (Sakigake) and Orphan Drug designations for ...